Literature DB >> 32868080

LncRNA GSEC promotes the proliferation, migration and invasion by sponging miR-588/ EIF5A2 axis in osteosarcoma.

Renfeng Liu1, Cheng Ju2, Feifei Zhang3, Xiaofeng Tang4, Jinhua Yan5, Jun Sun6, Bin Lv7, Yuhong Guo8, Yiping Liang9, Xiao-Bin Lv10, Zhiping Zhang11.   

Abstract

BACKGROUND: Long noncoding RNAs (LncRNAs) show dysregulation in a variety of cancers. However, the function and specific mechanism of LncRNA GSEC in the progression of osteosarcoma remain mostly unknown. In this study, we sought to elucidate the role and mechanism of LncRNA GSEC in the occurrence and progression of osteosarcoma.
METHODS: we examined the expression of LncRNA GSEC in osteosarcoma cell lines by quantitative real time PCR. In vitro experiments, including transwell assays, cck8 assays, and flow cytometry analysis have biologically demonstrated the effect of LncRNA GSEC on the proliferation and migration of osteosarcoma cell lines. Furthermore, the regulation of miR-588 by LncRNA GSEC was determined by luciferase reporter assay and quantitative real time PCR. What's more, subcutaneous tumor formation was performed in nude mice to monitor the growth of the tumor in vivo.
RESULTS: We found that the expression of LncRNA GSEC was up-regulated in osteosarcoma cell lines. Overexpression of LncRNA GSEC promoted the proliferating and migratory capacity, and inhibited the apoptosis of osteosarcoma cells. Conversely, knockdown of LncRNA GSEC resulted in the opposite effect. Mechanistically, we identified LncRNA GSEC functioned as the sponge of miR-588, thus inhibiting the miR-588/EIF5A2 signal pathway. In addition, the expression of miR-588 was negatively correlated with LncRNA GSEC, and the effect by silencing or overexpressing LncRNA GSEC could be rescued by the introduction of miR-588 mimics or inhibitors, respectively.
CONCLUSIONS: In summary, this study shows that LncRNA GSEC promotes the proliferation and invasion of OS through the regulation of miR-588/EIF5A2 pathway, which might provide a new strategy for the treatment of osteosarcoma in the future.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell proliferation; Invasion; LncRNA GSEC; Osteosarcoma; miR-588/ EIF5A2

Mesh:

Substances:

Year:  2020        PMID: 32868080     DOI: 10.1016/j.bbrc.2020.08.056

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  lncRNA GSEC Promotes the Progression of Triple Negative Breast Cancer (TNBC) by Targeting the miR-202-5p/AXL Axis.

Authors:  Jianhua Zhang; Chuang Du; Linfeng Zhang; Yan Wang; Yingying Zhang; Jingruo Li
Journal:  Onco Targets Ther       Date:  2021-04-20       Impact factor: 4.147

2.  LncRNA ZFAS1 regulates the proliferation, oxidative stress, fibrosis, and inflammation of high glucose-induced human mesangial cells via the miR-588/ROCK1 axis.

Authors:  Zhuang Geng; Bingzi Dong; Wenshan Lv; Zhongchao Wang; Xiang Wang; YaJing Huang; Yangang Wang; Lili Xu
Journal:  Diabetol Metab Syndr       Date:  2022-01-28       Impact factor: 3.320

3.  An Effective Hypoxia-Related Long Non-Coding RNA Assessment Model for Prognosis of Lung Adenocarcinoma.

Authors:  Yuanshuai Li; Xiaofang Sun
Journal:  Front Genet       Date:  2022-03-16       Impact factor: 4.599

4.  A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma.

Authors:  Jiahang Song; Yuanyuan Sun; Hui Cao; Zhengcheng Liu; Lei Xi; Changqing Dong; Rusong Yang; Ye Shi
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Comprehensive analysis of GSEC/miR-101-3p/SNX16/PAPOLG axis in hepatocellular carcinoma.

Authors:  Shangshang Hu; Jinyan Zhang; Guoqing Guo; Li Zhang; Jing Dai; Yu Gao
Journal:  PLoS One       Date:  2022-04-28       Impact factor: 3.240

6.  Systematic Analysis and Validation of the Prognosis, Immunological Role and Biology Function of the Ferroptosis-Related lncRNA GSEC/miRNA-101-3p/CISD1 Axis in Lung Adenocarcinoma.

Authors:  Xiulin Jiang; Yixiao Yuan; Lin Tang; Juan Wang; Dahang Zhang; Lincan Duan
Journal:  Front Mol Biosci       Date:  2022-03-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.